title: [The effect of statin treatment on inflammation in patients with metabolic syndrome].
abstract: OBJECTIVE
  Inflammation plays an important role in the pathogenesis of metabolic syndrome (MS). We investigated the effect of fluvastatin treatment on inflammatory markers in patients with MS.
  
  
  METHODS
  The study included 47 patients (36 females; 11 males; mean age 55+/-8 years) with MS. The diagnosis of MS was based on the presence of at least three criteria of the NCEP ATP III guidelines. All the patients received 80 mg fluvastatin treatment for six weeks. Laboratory parameters were measured before and after treatment, and flow cytometric analysis of peripheral blood leukocytes was performed. The results were compared with those of 47 age- and sex-matched healthy controls (33 females, 14 males; mean age 52+/-8 years).
  
  
  RESULTS
  Fluvastatin treatment resulted in significant decreases in levels of total cholesterol, LDL cholesterol, triglyceride (p<0.005), and C-reactive protein (p<0.05). Thirty-three patients (70.2%) had insulin resistance, which remained unchanged following treatment. Flow cytometric analysis after treatment showed significant decreases in total lymphocytes, and in surface antigens of CD16+56 and CD8+(CD28+) on leukocytes, CD11c on granulocytes, and a significant increase in the CD4/CD8 ratio (p<0.05). Compared to the control group, the mean baseline values of fluorescence density (FD) of CD14, CD11b, CD11c, and CD63 on monocytes, and CD11b and CD11c on granulocytes were significantly higher in patients with MS (p<0.05). Following fluvastatin treatment, there were significant decreases in the mean FD of CD3 on lymphocytes, and of CD11b and CD11c on both monocytes and granulocytes (p<0.05); of these, all FD values were similar to those in the control group (p>0.05).
  
  
  CONCLUSIONS
  Our data demonstrate that inflammation may have a significant role in the pathogenesis of MS and that this effect can be controlled with statin treatment.
authors.affiliation: Zonguldak Karaelmas Universitesi, Tip Fakültesi Kardiyoloji Anabilim Dali, Zonguldak, Turkey. drmustafaaydin@hotmail.com
authors.forename: Mustafa
authors.initials: M
authors.lastname: Aydin
authors.forename: Tolga
authors.initials: T
authors.lastname: Onuk
authors.forename: Sait Mesut
authors.initials: SM
authors.lastname: Doğan
authors.forename: Nesligül
authors.initials: N
authors.lastname: Yildirim
authors.forename: Erkan
authors.initials: E
authors.lastname: Demirci
authors.forename: Ezgi
authors.initials: E
authors.lastname: Kalaycioğlu
authors.forename: Hediye
authors.initials: H
authors.lastname: Madak
authors.forename: Ziyaettin
authors.initials: Z
authors.lastname: Aktop
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ali Cetiner
authors.forename: Muhammet Raşit
authors.initials: MR
authors.lastname: Sayin
authors.forename: Sibel
authors.initials: S
authors.lastname: Karaaslan
mesh_terms: D015703:Antigens, CD / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005434:Flow Cytometry; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D007333:Insulin Resistance; D018655:Lymphocyte Count; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D014280:Triglycerides; D000077340:Fluvastatin; D002097:C-Reactive Protein; D002784:Cholesterol